RM-MET / Metabolic and incretin signalling
Teduglutide
Also known as: GLP-2 analog
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Teduglutide is a GLP-2 analog, not a GLP-1 receptor agonist. A single amino-acid substitution relative to native GLP-2 changes its resistance to enzymatic degradation.
Evidence position
An FDA-labeled comparator and randomized human evidence support Grade A for the regulated presentation.
What the record does not establish
The literature and label do not verify the identity, strength, purity or sterility of another source.
Sources
- 01Gattex prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- U.S. label for a defined lyophilized teduglutide product
- Does not show
- Does not qualify a separate material or presentation
- 02Teduglutide randomized study in short-bowel intestinal failurePubMed
- Shows
- Randomized human data for the finished investigational presentation
- Does not show
- Does not establish third-party lot quality
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Teduglutide
- CID
- 16139605
- Formula
- C164H252N44O55S
- Mass
- 3752.1
PUBMED / FOUND RECORDS
- Definition, classification, and causes of short bowel syndrome.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition / 2023 MayPMID 37115031 / DOI 10.1002/ncp.10955
- Understanding short bowel syndrome: Current status and future perspectives.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver / 2020 MarPMID 31892505 / DOI 10.1016/j.dld.2019.11.013
- Updates in Intestinal Failure Management.Journal of clinical medicine / 2025 Apr 28PMID 40364063 / DOI 10.3390/jcm14093031
- Teduglutide. / 2006PMID 36701512
- European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN: Part 2: Screening, Special Populations, Nutritional Goals, Supportive Care, Primary Care Perspective.United European gastroenterology journal / 2025 JunPMID 40088199 / DOI 10.1002/ueg2.70011
CLINICALTRIALS.GOV / FOUND RECORDS
- TED_ORG: Study on Short Bowel SyndromeRECRUITING / NA / Meyer Children's Hospital IRCCSNCT07400783 / DIRECT intervention MATCH: Teduglutide
- Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008COMPLETED / PHASE2 / ShireNCT00308438 / DIRECT intervention MATCH: Teduglutide
- Bridging Intestinal Failure With Teduglutide - a Case ReportCOMPLETED / NO PHASE / Medical University of ViennaNCT04916665 / DIRECT intervention MATCH: Teduglutide
- Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal FunctionCOMPLETED / PHASE1 / NycomedNCT01028768 / DIRECT intervention MATCH: Teduglutide
- Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy ParticipantsCOMPLETED / PHASE1 / ShireNCT00819468 / DIRECT intervention MATCH: Teduglutide